TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05687227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education and counseling
Description: Online education and counseling regarding gynecological examination
Study: NCT04877678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bepotastine
Description: 10 mg Bepotastine, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo, twice a day
Study: NCT05582044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-body Negative Pressure (-25 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-body Negative Pressure (-15 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-body Negative Pressure (-15 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-body Neutral Pressure (0 mmHg)
Description: In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-body Neutral Pressure (0 mmHg)
Description: In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
Study: NCT05855655

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Queer Resilience (MBQR)
Description: This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Queer Resilience (MBQR)
Description: This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30).
Study: NCT04978051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firazyr
Description: Icatibant 10 MG/ML Prefilled Syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
Study: NCT06380790

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser-aided csf
Description: Laser-aided csf before leveling and alignment

Intervention type: OTHER
Group type: OTHER
Intervention: placebo laser-aided csf
Description: placebo laser-aided csf before leveling and alignment
Study: NCT06120959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization exercise
Description: The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Description: The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
Study: NCT05031689

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
Description: Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract
Description: Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
Study: NCT03952234

Intervention type: DRUG
Group type: OTHER
Intervention: L-Citrulline
Description: To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
Study: NCT05372393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration anaesthesia in carpal tunnel release
Description: The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal median nerve block with local infiltration anaesthesia in carpal tunnel release
Description: The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
Study: NCT04831437

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated EBRT
Description: EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard EBRT
Description: EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
Study: NCT04187131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: augmented reality
Description: The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
Study: NCT05547386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT06120959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise
Description: The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
Study: NCT05831904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
Study: NCT05863403

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise
Description: Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
Study: NCT04956081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-navigated Transcranial Magnetic Stimulation (TMS)
Description: TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-navigated Transcranial Magnetic Stimulation (TMS)
Description: TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
Study: NCT05541523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy
Description: The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based therapy
Description: The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
Study: NCT06402968

Intervention type: DRUG
Intervention: Clevidipine Injection
Description: Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.

Intervention type: DRUG
Intervention: Alternate IV Antihypertensive Regimen
Description: The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.
Study: NCT04945213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: 5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
Study: NCT05289206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine - ChAdOx1-S/nCoV-19 [recombinant]
Description: ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
Study: NCT05793216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VestibulOTherapy
Description: For this study, the following activity-orientated interventions will occur within the natural learning environments so that generous opportunities exist for neural plasticity and growth.~Each student will be engaged in 20-30 minutes/day of intermittent classroom activities, plus 20-30- minutes of daily stability work embedded into classroom routines including stabilizing self on a Hokki stool or t-stool or standing on a balance board during sedentary work, such as circle time or read-a-loud.
Study: NCT05718206

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetocardiography
Description: Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiography
Description: Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
Study: NCT04685499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
Study: NCT05836129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice
Description: See previous description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress reduction class (online)
Description: See previous description
Study: NCT05108688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 30 mg tablet once daily for 3 successive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Sumatriptan 50 mg tablet once daily for 3 successive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily for 3 successive days.
Study: NCT05161182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, low carbohydrate diet
Description: Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat, high carbohydrate diet
Description: Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
Study: NCT05295745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy and multidisciplinary intervention
Description: The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included
Study: NCT05454397

Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observational study, no intervention
Study: NCT05110326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERGON Technique
Description: * Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching
Description: * The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group
Study: NCT04348071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive 10 mg ruxolitinib twice daily.
Study: NCT04289558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
Study: NCT04543916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 50 MG
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 MG
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 200 MG
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 400
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 600
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15
Study: NCT04978051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SoC
Description: The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
Study: NCT04543916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (RP2D)
Description: orally, once per day
Study: NCT05088044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training porogram
Description: training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
Study: NCT05468645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Hemay005
Description: Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
Study: NCT06231706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic-like nut and seed mix
Description: A mixture of nuts, seeds and other plant based ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic-like nut and seed mix
Description: A mixture of nuts, seeds and other plant based ingredients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bread Crouton
Description: A commercially available bread crouton product.
Study: NCT06185608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Description: A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
Study: NCT06231706

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic capsule
Description: Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White bread and low fat spread
Description: Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)